Literature DB >> 22766605

HCV infection prevalence lower than expected among 18-40-year-old injection drug users in San Diego, CA.

Richard S Garfein1, Amanda Rondinelli, Richard F W Barnes, Jazmine Cuevas, Mitcheal Metzner, Michele Velasquez, David Rodriguez, Meredith Reilly, Jian Xing, Eyasu H Teshale.   

Abstract

San Diego, California shares the world's busiest land border crossing with Tijuana, Mexico-a city where 95 % of injection drug users (IDUs) test hepatitis C virus (HCV) antibody-positive. Yet, little is known about the prevalence and risk behaviors for HCV among IDUs in San Diego. In 2009-2010, 18-40-year-old IDUs in San Diego County completed a risk assessment interview and serologic testing for HCV and HIV infection. Recruitment involved respondent-driven sampling, venue-based sampling at a syringe exchange program, and convenience sampling. Correlates of HCV infection were identified by multivariable logistic regression. Among 510 current IDUs, 26.9 % (95 % CI 23.0-30.7 %) and 4.2 % (95 % CI 2.4-5.9 %) had been infected with HCV and HIV, respectively. Overall, median age was 28 years; 74 % were male; 60 % white and 29 % Hispanic; and 96 % were born in the U.S. Median years of injecting was 6; 41 % injected daily; 60 % injected heroin most often; 49 % receptively shared syringes and 68 % shared other injection paraphernalia; and only 22 % reported always using new syringes in the past 3 months. Two thirds had ever traveled to Mexico and 19 % injected in Mexico. HCV infection was independently associated with sharing injection paraphernalia (adjusted odds ratio [AOR] = 1.69) and SEP use (AOR = 2.17) in the previous 3 months, lifetime history of drug overdose (AOR = 2.66), and increased years of injecting (AOR = 2.82, all P values <0.05). Controlling for recruitment method did not alter results. HCV infection prevalence among IDUs in San Diego was modest compared to other US cities and much lower than Tijuana. Given that known individual-level HCV risk factors were common in San Diego, the city's lower HCV prevalence might be due to differences in social and structural factors between the cities.

Entities:  

Mesh:

Year:  2013        PMID: 22766605      PMCID: PMC3665980          DOI: 10.1007/s11524-012-9728-0

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  32 in total

1.  Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users.

Authors:  Grace E Macalino; David D Celentano; Carl Latkin; Steffanie A Strathdee; David Vlahov
Journal:  AIDS Educ Prev       Date:  2002-10

Review 2.  Review of sampling hard-to-reach and hidden populations for HIV surveillance.

Authors:  Robert Magnani; Keith Sabin; Tobi Saidel; Douglas Heckathorn
Journal:  AIDS       Date:  2005-05       Impact factor: 4.177

3.  Heroin overdose among young injection drug users in San Francisco.

Authors:  Kristen C Ochoa; Peter J Davidson; Jennifer L Evans; Judith A Hahn; Kimberly Page-Shafer; Andrew R Moss
Journal:  Drug Alcohol Depend       Date:  2005-06-14       Impact factor: 4.492

4.  Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco.

Authors:  J A Hahn; K Page-Shafer; P J Lum; K Ochoa; A R Moss
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

5.  Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection.

Authors:  D M Patrick; M W Tyndall; P G Cornelisse; K Li; C H Sherlock; M L Rekart; S A Strathdee; S L Currie; M T Schechter; M V O'Shaughnessy
Journal:  CMAJ       Date:  2001-10-02       Impact factor: 8.262

6.  Sharing of drug preparation equipment as a risk factor for hepatitis C.

Authors:  H Hagan; H Thiede; N S Weiss; S G Hopkins; J S Duchin; E R Alexander
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

7.  Traveling young injection drug users at high risk for acquisition and transmission of viral infections.

Authors:  Judith A Hahn; Kimberly Page-Shafer; Jamye Ford; Alan Paciorek; Paula J Lum
Journal:  Drug Alcohol Depend       Date:  2007-11-05       Impact factor: 4.492

8.  Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.

Authors:  Joseph J Amon; Richard S Garfein; Linda Ahdieh-Grant; Gregory L Armstrong; Lawrence J Ouellet; Mary H Latka; David Vlahov; Steffanie A Strathdee; Sharon M Hudson; Peter Kerndt; Don Des Jarlais; Ian T Williams
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

9.  HCV and HIV counseling and testing integration in California: an innovative approach to increase HIV counseling and testing rates.

Authors:  Thomas J Stopka; Clark Marshall; Ricky N Bluthenthal; David S Webb; Steven R Truax
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

10.  Sexual and injection-related risks in Puerto Rican-born injection drug users living in New York City: A mixed-methods analysis.

Authors:  Camila Gelpí-Acosta; Holly Hagan; Samuel M Jenness; Travis Wendel; Alan Neaigus
Journal:  Harm Reduct J       Date:  2011-10-17
View more
  20 in total

1.  Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance.

Authors:  Rachel E Gicquelais; Betsy Foxman; Joseph Coyle; Marisa C Eisenberg
Journal:  Epidemics       Date:  2019-02-28       Impact factor: 4.396

2.  Patterns of drug use, risky behavior, and health status among persons who inject drugs living in San Diego, California: a latent class analysis.

Authors:  Alexis M Roth; Richard A Armenta; Karla D Wagner; Scott C Roesch; Ricky N Bluthenthal; Jazmine Cuevas-Mota; Richard S Garfein
Journal:  Subst Use Misuse       Date:  2014-10-14       Impact factor: 2.164

3.  Prevalence and Correlates of Heroin-Methamphetamine Co-Injection Among Persons Who Inject Drugs in San Diego, California, and Tijuana, Baja California, Mexico.

Authors:  Meredith C Meacham; Steffanie A Strathdee; Gudelia Rangel; Richard F Armenta; Tommi L Gaines; Richard S Garfein
Journal:  J Stud Alcohol Drugs       Date:  2016-09       Impact factor: 2.582

4.  Continued Transmission of HIV Among Young Adults Who Inject Drugs in San Francisco: Still Room for Improvement.

Authors:  Ali Mirzazadeh; Jennifer L Evans; Judith A Hahn; Jennifer Jain; Alya Briceno; Stephen Shiboski; Paula J Lum; Christopher Bentsen; Geoff Davis; Kathy Shriver; Melanie Dimapasoc; Mars Stone; Michael P Busch; Kimberly Page
Journal:  AIDS Behav       Date:  2018-04

5.  Comparison of Three Popular Methods for Recruiting Young Persons Who Inject Drugs for Interventional Studies.

Authors:  Melissa G Collier; Richard S Garfein; Jazmine Cuevas-Mota; Eyasu H Teshale
Journal:  J Urban Health       Date:  2017-08       Impact factor: 3.671

6.  Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study.

Authors:  M Schulte; Y Hser; A Saxon; E Evans; L Li; D Huang; M Hillhouse; C Thomas; W Ling
Journal:  J Community Health       Date:  2015-10

7.  A fragmented code: The moral and structural context for providing assistance with injection drug use initiation in San Diego, USA.

Authors:  Andy Guise; Jason Melo; Maria Luisa Mittal; Claudia Rafful; Jazmine Cuevas-Mota; Peter Davidson; Richard S Garfein; Dan Werb
Journal:  Int J Drug Policy       Date:  2018-03-07

8.  Structural factors associated with methamphetamine smoking among female sex workers in Tijuana, Mexico.

Authors:  Erin E Conners; Tommi L Gaines; Steffanie A Strathdee; Carlos Magis-Rodriguez; Kimberly C Brouwer
Journal:  Drug Alcohol Rev       Date:  2017-12-07

9.  Effect of legal status of pharmacy syringe sales on syringe purchases by persons who inject drugs in San Francisco and San Diego, CA.

Authors:  Saira S Siddiqui; Richard F Armenta; Jennifer L Evans; Michelle Yu; Jazmine Cuevas-Mota; Kimberly Page; Peter Davidson; Richard S Garfein
Journal:  Int J Drug Policy       Date:  2015-06-24

10.  Mycobacterium tuberculosis infection among persons who inject drugs in San Diego, California.

Authors:  R F Armenta; K M Collins; S A Strathdee; M A Bulterys; F Munoz; J Cuevas-Mota; P Chiles; R S Garfein
Journal:  Int J Tuberc Lung Dis       Date:  2017-04-01       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.